Intracrine androgen biosynthesis and drug resistance
Membership Made for You At Ivm Health, we recognize that each persons health journey is unique
Several active research areas include: Metabolic dysfunction-associated steatotic liver disease (MASLD) : Multiple trials are evaluating semaglutide's effects on liver fat content and biomarkers, with preliminary data suggesting potential benefits in reducing hepatic steatosis and improving liver enzyme profiles Chronic kidney disease : Studies examining renal outcomes in patients with type 2 diabetes and established kidney disease, building on secondary analyses from SUSTAIN 6 showing reduced progression of diabetic nephropathy Obstructive sleep apnea : Ongoing trials investigating whether weight loss achieved with semaglutide improves sleep apnea severity and related cardiovascular outcomes Addiction and substance use disorders : Early-phase research exploring GLP-1 receptor agonists' potential effects on reward pathways and addictive behaviors, though this remains highly preliminary Alzheimer's disease and cognitive function : Preclinical evidence suggesting neuroprotective properties has prompted clinical trials examining cognitive outcomes in at-risk populations Researchers are also investigating combination therapies , such as cagrilintide plus semaglutide (CagriSema), which is currently under development
Registration number AM.01.07.01.003.R.000945.07.24 of 01.07.2024 Release form 60 capsules, 0.2 g Keep out of reach of children, at a temperature not exceeding 25 C Shelf life: 3 years Manufacturer/organization accepting claims: CJSC Evalar, Russia, Altai Territory, 659332, Biysk, Socialisticheskaya Str., 23/6, www.evalar.ru
